Did This Big Pharma Giant Sink or Swim Last Quarter?

Analyzing a stock for the first time can be daunting, but one of the best ways to familiarize yourself with a new company is to crack open its latest earnings report. Take Dow component Pfizer as an example. Sure, it has a long history of developing new medicines and pays an attractive 3.4% yield, but is its underlying business healthy? Did its revenue grow or contract last quarter? Did any major patent expirations weigh on its total sales?

In the following video, taken from the Motley Fool's health care show Market Checkup, health care analysts David Williamson and Max Macaluso discuss Pfizer's second-quarter results and how the company stacked up against one of its big pharma peers.

One of the best parts of owning big pharma stocks like Pfizer is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

The article Did This Big Pharma Giant Sink or Swim Last Quarter? originally appeared on Fool.com.

David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.